Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BASIC - Better treatment for acute sinusitis in primary care
2020-000429-17Phase 4Completed
- Sponsor
- University of Oslo
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of chloramphenicol in acute rhinosinusitis (ARS) (3 arms), sponsored by University of Oslo. Primary endpoint: Time to symptom resolution. Started Apr 2021; status: completed.
02
Drugs
chloramphenicol
03
Conditions
acute rhinosinusitis (ARS)
Beyond the preview
Go deeper on 2020-000429-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000429-17.